JOSEPH SMITH JR. received the Huggins Medal from The Society of Urologic Oncology, the society's highest honor, for his lifetime contributions to treatment for patients with genitourinary neoplasms. Smith is a professor of Urologic Surgery at Vanderbilt University Medical Center.
FDA's Class II 510(k) clearance process for medium-risk devices—a category that includes the power morcellator—is inadequate, because it does not focus on risk assessment, according to Bill Vodra, a former associate chief counsel for drugs at FDA.
BHRAMAR MUKHERJEE was appointed associate director for population science research at The University of Michigan Comprehensive Cancer Center, effective Jan. 15, 2016.
JOHN “DREW” RIDGE was elected president of the medical staff at Fox Chase Cancer Center – Temple Health. Ridge serves as chief of Head and Neck Surgery and Louis Della Penna Family Chair in Head and Neck Oncology.
The FDA Office of Criminal Investigations is being asked to determine why the agency has failed to detect the upstaging of cancers in women who had been operated on with a power morcellator.
Friends call him The Hoomanator, a darkly comical conflation of his first name, Hooman, and morcellator, the medical device he has aggressively campaigned against.
DEBBIE'S DREAM FOUNDATION: Curing Stomach Cancer launched two research grants totaling $200,000 for the 2015-2016 grant cycle. A Career Development Award for $150,000 and a Young Fellowship Grant for $50,000 are being offered.
MIA LEVY was named director of Cancer Health Information and Strategy at Vanderbilt-Ingram Cancer Center. Levy is the Ingram Assistant Professor of Cancer Research and director of Cancer Clinical Informatics at the center.
ROBERT HAUSER was named vice president of clinical analytics at Cancer Treatment Centers of America Medicine & Science.